Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

New SHTAC report: Peginterferon alfa and ribavirin for people with chronic hepatitis C

Published: 8 May 2011
Hepatitis C research

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for people with chronic hepatitis C who are eligible for shortened treatment, re-treatment or who are co-infected with HIV, is now available

The report is published in the Health Technology Assessment monograph series and was produced by SHTAC to inform an updated technology appraisal by the National Institute for Health and Clinical Excellence (NICE).  The study found that patients may be successfully treated with a shorter course of peginterferon and ribavirin combination therapy without compromising the likelihood of achieving a sustained virological response. The economic evaluation showed that treatment with peginterferon alfa in specified subgroups of patients yielded quality-of-life gains without excessive increases in costs.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.